Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
| 0.0001 | |
| 0.0001 | |
| - | |
| 0.0001 | |
| 0.0001 | |
| 0-0.07 | |
| 2 984 K | |
| 42 623 K | |
| 1 104 K | |
| 0 | |
| 36.196 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Exelixis, Inc. EXEL recently announced that it has initiated the dose-escalation stage of the first-in-human phase I study of investigational candidate XL114. XL114 is a novel anti-cancer compound th...
NEW YORK, April 11, 2022 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Kaleido Biosciences, Inc. (“Kaleido Biosciences” or...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
